CVS Makes Exclusive Deal to Cover Amgen’s Cholesterol Drug
- Big drug benefit manager will cover Amgen's PCSK9 drug Repatha
- CVS won't cover competing cholesterol medicine from Sanofi
This article is for subscribers only.
CVS Health Corp.’s drug-benefits unit will cover Amgen Inc.’s new cholesterol-cutting injections while excluding a competing treatment from Sanofi and Regeneron Pharmaceuticals Inc., pushing for savings from medications that list for more than $14,000 a year.
The decision, which applies to workers whose employers use CVS Health for drug coverage, shows that benefit managers are continuing to be aggressive about setting exclusive deals with drugmakers to get better prices for expensive new therapies.